| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Herbert Y Meltzer, Larry Alphs, Alan I Green, A Carlo Altamura, Ravi Anand, Alberto Bertoldi, Marc Bourgeois, Guy Chouinard, M Zahur Islam, John Kane, Ranga Krishnan, J P Lindenmayer, Steven Potki. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of general psychiatry. vol 60. issue 1. 2003-01-23. PMID:12511175. |
clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (intersept). |
2003-01-23 |
2023-08-12 |
Not clear |
| G Adler, S Grieshaber, V Faude, B Thebaldi, H Dressin. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. Pharmacopsychiatry. vol 35. issue 5. 2003-01-17. PMID:12237790. |
clozapine in patients with chronic schizophrenia: serum level, eeg and memory performance. |
2003-01-17 |
2023-08-12 |
Not clear |
| Cara L Alfaro, Marianne Wudarsky, Rob Nicolson, Peter Gochman, Alexandra Sporn, Marge Lenane, Judith L Rapopor. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of child and adolescent psychopharmacology. vol 12. issue 2. 2003-01-03. PMID:12188977. |
patients with a diagnostic and statistical manual of mental disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15.4 +/- 8.1 mg/day [0.27 +/- 0.15 mg/kg/day]), clozapine (n = 30, mean dose 269.9 +/- 173.3 mg/day [4.4 +/- 2.6 mg/kg/day]), or olanzapine (n = 12, mean dose 17.5 +/- 2.8 mg/day [0.30 +/- 0.13 mg/kg/day]). |
2003-01-03 |
2023-08-12 |
Not clear |
| Stephen R Marder, Susan M Essock, Alexander L Miller, Robert W Buchanan, John M Davis, John M Kane, Jeffrey Lieberman, Nina R Schoole. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia bulletin. vol 28. issue 1. 2002-12-19. PMID:12047022. |
the group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: first generation (fgas) and second generation (sgas) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on fgas and sgas; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics. |
2002-12-19 |
2023-08-12 |
Not clear |
| S Iverson, N Zahid, J P Uetrech. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chemico-biological interactions. vol 142. issue 1-2. 2002-12-19. PMID:12399162. |
dmp 406 is a clozapine analogue developed by dupont-pharma for the treatment of schizophrenia. |
2002-12-19 |
2023-08-12 |
Not clear |
| Kent Jardemark, Marie-Louise Wadenberg, Pernilla Grillner, Torgny H Svensso. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia. Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054059. |
the findings that dopamine d3 and d4 receptors are highly expressed in limbic and cortical areas (d4 more than d3), and the fact that the atypical drug clozapine has preferential affinity for the d4 receptors have suggested an involvement of these receptors in schizophrenia. |
2002-12-17 |
2023-08-12 |
Not clear |
| K P Hayhurst, P Brown, S W Lewi. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. Journal of psychopharmacology (Oxford, England). vol 16. issue 2. 2002-12-17. PMID:12095076. |
these findings suggest that clozapine is a clinically and cost-effective intervention for severe schizophrenia in routine clinical settings. |
2002-12-17 |
2023-08-12 |
Not clear |
| K Alptekin, B B Kivirci. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. International clinical psychopharmacology. vol 17. issue 5. 2002-12-03. PMID:12177588. |
we report three patients with schizophrenia who demonstrated improvement of tardive dyskinesia following treatment with quetiapine; two of them were unable to use clozapine because of intolerable side-effects. |
2002-12-03 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Pal Czobor, Jan Volavka, Jeffrey A Lieberman, Leslie Citrome, Brian Sheitman, Miranda Chakos, Joseph P McEvo. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. The Journal of clinical psychiatry. vol 63. issue 10. 2002-11-15. PMID:12416603. |
we present an open-label prospective 14-week trial with olanzapine in patients with schizophrenia and schizoaffective disorder whose treatment resistance to clozapine, olanzapine, risperidone, and haloperidol had been determined prospectively. |
2002-11-15 |
2023-08-12 |
Not clear |
| Hreinn Stefansson, Engilbert Sigurdsson, Valgerdur Steinthorsdottir, Soley Bjornsdottir, Thordur Sigmundsson, Shyamali Ghosh, Jon Brynjolfsson, Steinunn Gunnarsdottir, Omar Ivarsson, Thomas T Chou, Omar Hjaltason, Birgitta Birgisdottir, Helgi Jonsson, Vala G Gudnadottir, Elsa Gudmundsdottir, Asgeir Bjornsson, Brynjolfur Ingvarsson, Andres Ingason, Sigmundur Sigfusson, Hronn Hardardottir, Richard P Harvey, Donna Lai, Mingdong Zhou, Daniela Brunner, Vincent Mutel, Acuna Gonzalo, Greg Lemke, Jesus Sainz, Gardar Johannesson, Thorkell Andresson, Daniel Gudbjartsson, Andrei Manolescu, Michael L Frigge, Mark E Gurney, Augustine Kong, Jeffrey R Gulcher, Hannes Petursson, Kari Stefansso. Neuregulin 1 and susceptibility to schizophrenia. American journal of human genetics. vol 71. issue 4. 2002-10-28. PMID:12145742. |
we also demonstrate that the behavioral phenotypes of the nrg1 hypomorphs are partially reversible with clozapine, an atypical antipsychotic drug used to treat schizophrenia. |
2002-10-28 |
2023-08-12 |
mouse |
| Herbert Y Meltze. Commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18-S27. Psychopharmacology. vol 163. issue 1. 2002-10-16. PMID:12185394. |
commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." |
2002-10-16 |
2023-08-12 |
Not clear |
| Carla M Canuso, Jill M Goldstein, Joanne Wojcik, Ree Dawson, Danielle Brandman, Anne Klibanski, Joseph J Schildkraut, Alan I Gree. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry research. vol 111. issue 1. 2002-10-10. PMID:12140115. |
sixteen premenopausal women with schizophrenia and schizoaffective disorder, eight treated with an antipsychotic with prolactin-elevating potential (five with typical antipsychotics and three with risperidone) and eight treated with an antipsychotic with prolactin-sparing potential (seven with olanzapine and one with clozapine), were studied for eight weeks. |
2002-10-10 |
2023-08-12 |
human |
| Herbert Y Meltze. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Current psychiatry reports. vol 4. issue 4. 2002-10-09. PMID:12126596. |
there is significant evidence suggesting that clozapine reduces the suicide rate in patients with schizophrenia and schizoaffective disorder. |
2002-10-09 |
2023-08-12 |
Not clear |
| Herbert Y Meltze. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Current psychiatry reports. vol 4. issue 4. 2002-10-09. PMID:12126596. |
the results support the superiority of clozapine over olanzapine to reduce the risk of suicidality and suggest its use should be considered for all patients with schizophrenia with high risk for suicide. |
2002-10-09 |
2023-08-12 |
Not clear |
| Zoe Thornton-Jones, Joanna C Neill, Gavin P Reynold. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. Journal of psychopharmacology (Oxford, England). vol 16. issue 1. 2002-10-08. PMID:11949769. |
the weight gain associated with several antipsychotic drugs, most notably the newer 'atypical' compounds olanzapine and clozapine, introduces problems of compliance and morbidity in the treatment of schizophrenia. |
2002-10-08 |
2023-08-12 |
rat |
| Scott P Baymiller, Patricia Ball, Robert P McMahon, Robert W Buchana. Weight and blood pressure change during clozapine treatment. Clinical neuropharmacology. vol 25. issue 4. 2002-09-27. PMID:12151907. |
weight gain and mean arterial blood pressure changes were assessed in 61 outpatients with schizophrenia who were randomly assigned to either clozapine or haloperidol in a 10-week parallel group, double-blind study and in 55 patients who chose to continue to receive clozapine in a subsequent 1-year open-label prospective study. |
2002-09-27 |
2023-08-12 |
Not clear |
| Palmiero Monteleone, Michele Fabrazzo, Alfonso Tortorella, Silvestro La Pia, Mario Ma. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. Journal of clinical psychopharmacology. vol 22. issue 4. 2002-09-18. PMID:12172344. |
body weight and plasma levels of leptin were prospectively measured in 22 patients (13 men and 9 women) with drug-resistant schizophrenia undergoing a long-term treatment with clozapine. |
2002-09-18 |
2023-08-12 |
Not clear |
| Ines Gaertner, Hans Jorg Gaertner, Reinhard Vonthein, Klaus Diet. Prospective 6-year trial with clozapine: negative symptoms in outpatients with schizophrenia improve despite intermittent positive symptoms. Journal of clinical psychopharmacology. vol 22. issue 4. 2002-09-18. PMID:12172348. |
prospective 6-year trial with clozapine: negative symptoms in outpatients with schizophrenia improve despite intermittent positive symptoms. |
2002-09-18 |
2023-08-12 |
Not clear |
| Paul Oestreiche. Genaissance pharmaceuticals, inc. Pharmacogenomics. vol 3. issue 2. 2002-08-23. PMID:11972448. |
the company has initiated the development of its own pipeline of products -- hap clozapine for schizophrenia and hap statin for cholesterol management -- utilizing its proprietary genetic markers. |
2002-08-23 |
2023-08-12 |
Not clear |
| Nadine Snyder, Gerald Goldstei. Decreased psychopathology & family burden. Associated with clozapine treatment of patients with refractory schizophrenia. Journal of psychosocial nursing and mental health services. vol 40. issue 5. 2002-08-20. PMID:12016691. |
associated with clozapine treatment of patients with refractory schizophrenia. |
2002-08-20 |
2023-08-12 |
Not clear |